CD19-CART Treatment for ALL

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

May 6, 2020

Study Completion Date

September 15, 2020

Conditions
Acute Leukemia
Interventions
BIOLOGICAL

CD19 CART

Patients will get one course of CART treatment with the dose of 0.5-5\*10\~6/KgBW.

Trial Locations (1)

200240

Shanghai Bioray Inc., Shanghai

Sponsors
All Listed Sponsors
collaborator

Second Xiangya Hospital of Central South University

OTHER

lead

Bioray Laboratories

INDUSTRY

NCT03232619 - CD19-CART Treatment for ALL | Biotech Hunter | Biotech Hunter